1. Home
  2. BQ vs ENVB Comparison

BQ vs ENVB Comparison

Compare BQ & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boqii Holding Limited representing

BQ

Boqii Holding Limited representing

HOLD

Current Price

$0.83

Market Cap

7.7M

ML Signal

HOLD

Logo Enveric Biosciences Inc.

ENVB

Enveric Biosciences Inc.

HOLD

Current Price

$1.46

Market Cap

8.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BQ
ENVB
Founded
2008
1994
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
8.1M
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
BQ
ENVB
Price
$0.83
$1.46
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.7M
99.0K
Earning Date
01-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$39,914,675.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.65
$0.56
52 Week High
$72.74
$13.25

Technical Indicators

Market Signals
Indicator
BQ
ENVB
Relative Strength Index (RSI) 41.02 51.87
Support Level $0.70 $1.17
Resistance Level $0.89 $1.53
Average True Range (ATR) 0.05 0.09
MACD -0.02 0.01
Stochastic Oscillator 2.11 79.99

Price Performance

Historical Comparison
BQ
ENVB

About BQ Boqii Holding Limited representing

Boqii Holding Ltd is a pet-focused platform in China. It offer a truly one-stop destination that pet parents in China may go to get everything it need for their pets and share their passion for pet parenting. It operate a pet-focused online retail business in China's pet market in terms of GMV. The company operates in single segment. This segment is engaged in pet products sales and online marketing and information services and other. All the company's revenues is derived from The PRC.

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

Share on Social Networks: